Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF): 2011-2024

Historic Depreciation & Amortization (CF) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $5.7 million.

  • Agios Pharmaceuticals' Depreciation & Amortization (CF) rose 2.16% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 7.22%. This contributed to the annual value of $5.7 million for FY2024, which is 14.65% down from last year.
  • As of FY2024, Agios Pharmaceuticals' Depreciation & Amortization (CF) stood at $5.7 million, which was down 14.65% from $6.6 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Depreciation & Amortization (CF) peaked at $9.8 million during FY2020, and registered a low of $5.7 million during FY2024.
  • Over the past 3 years, Agios Pharmaceuticals' median Depreciation & Amortization (CF) value was $6.6 million (recorded in 2023), while the average stood at $6.9 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Depreciation & Amortization (CF) increased by 21.04% in 2020 and then declined by 22.66% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $9.8 million in 2020, then fell by 5.62% to $9.2 million in 2021, then fell by 7.32% to $8.6 million in 2022, then declined by 22.66% to $6.6 million in 2023, then dropped by 14.65% to $5.7 million in 2024.